Global Biotech Leader

Beyond Symptomatic Relief.
Restoring the Brain.

Developing First-in-Class PKA/PKG Activators to fundamentally reverse neurodegenerative diseases.

The Global Crisis

Alzheimer's Disease affects over 55 million people globally. Current FDA-approved drugs like Aricept only provide symptomatic relief. Even newer antibody drugs like Leqembi only slow disease progress by ~27% and do not stop progression.

Unmet Medical Needs

  • Lack of Disease-Targeting Therapeutics (DTT).
  • No FDA-approved PDE inhibitors for humans.
The Origin

"Alzheimer's is not a life sentence."

GHPHARM was not founded as a business concept. It was founded to save a life.

2009

The Mother's Diagnosis

Founder Dr. Gil Hong Park's mother was diagnosed with Vascular Dementia. As a molecular biologist, Dr. Park refused to accept the medical consensus that dementia is "irreversible". He dedicated his life to finding a cure, pivoting 40 years of molecular R&D to save his mother.

R&D
Source Material

Pteridium aquilinum

Bracken Fern R&D

The Discovery: Pterosin D

After years of exhaustive R&D, Dr. Park identified Pterosin D — a natural small molecule derived from Pteridium aquilinum — as a first-in-class dual activator of the PKA/PKG pathway.

Extreme Scarcity Barrier

Natural extraction was once impossibly expensive, requiring an investment of $50 million per kilogram ($50M/kg), which initially rendered it commercially unviable for global therapeutic use.

2019
Breakthrough

The Scalability Innovation

Dr. Park successfully developed a world-first mass synthesis platform for Pterosin D, reducing production costs by 1,000x. This transformed a rare compound into a scalable pharmaceutical reality.

Natural Cost
$1,000/Unit
Synthetic (GHPHARM)
1/1000 Cost
Today

Patient Zero: Full Recovery

"After 6 months of treatment, medical records verified that my mother's cognitive levels had returned to the normal range."

Target Patient
Age 88 • Vascular Dementia & AD
Clinical Status
Verified Recovery

*Verified by Korea University Hospital & SCH Hospital Records. Featured in 2024 TV Interview.

"This medicine saved the founder's mother. Now, our mission is to scale this technology to save millions of families worldwide."

View Scientific Evidence
Mechanism of Action

Fundamental Recovery: Pterosin D

Pterosin D directly modulates the PKA and PKG pathways simultaneously to trigger fundamental neuro-regeneration.

External Stimuli
  • • Growth factors
  • • Hormones
  • • Toxins / Trauma
  • • Environment
HOOHO
Pterosin D : 0.025 nM

Potency: 25pM / CNS Permeable

Pathway A
PKA
cAMP Activation
Pathway B
PKG
cGMP Activation
Therapeutic Axis
BDNF / CREB
  • ● Neuronal Proliferation
  • ● Synaptic Plasticity
  • ● Adult Neurogenesis
  • ● Circadian Rhythm
  • ● Addiction Treatment
25pM
Potency
20.9Pe
CNS Permeability
27.4%
Bioavailability
100%
Memory Recovery

Preclinical Validation

Rigorous in vivo and in vitro studies confirm superior potency, safety, and bioavailability.

Potency (EC50)
25 pM

Extremely high affinity for PKA

Brain Permeability
20.9

Pe (10⁻⁶ cm/s) - High (CNS+)

Bioavailability
27.4%

Excellent oral absorption

Efficacy
100%

Memory recovery in 5xFAD mice

Superior Efficacy vs Competitors

Morris Water Maze (Memory Recovery)

Mirodenafil (Competitor) 80% Recovery
Pterosin D (GHPharm) 100% Recovery

*Pterosin D-fed AD mice recognized the platform 30% faster than normal mice.

Comprehensive Safety Profile

  • Non-toxic: Confirmed in GLP and non-GLP toxicity tests.
  • Cardiac Safety: Low hERG inhibition (IC50 150.7 µM).
  • Metabolic Safety: No inhibition of CYPs.

Strategic IP & Development Roadmap

Our path to global commercialization through strategic clinical milestones in Korea and the USA.

Clinical Development Plan

2025 - 2031+
2025
2026
2027
2028
2029
2030
2031+
Pre-Clinical Phase
Pharmacology
PK / ADME
Formulation & CMC
GLP Toxicology
Clinical Execution
Korea FDA
Phase I
Phase II
Mild/Mod/Sev
Phase III
CONDITIONAL NDA
USA FDA
IND Filing
Phase II Clinical Program
Active Cohorts
COND. NDA

Global Patent Protection

KR Registered
US Registered
EU Registered
CN Registered

Expanded Indications

Dementia Alzheimer's, Vascular, Parkinson's
Neuropsychiatric Depression, Autism, ADHD
Bone Health Osteoporosis, Fracture
Commercial Reality

Market Validation & Scalability

GHPHARM is not just an R&D lab. We have established GHPharm USA Inc. and are actively generating revenue through functional health products validated for safety and cognitive benefits.

  • Cost Efficiency: Estimated production cost of ~$10/month.
  • US Presence: Products available on Amazon, Walmart, eBay.
  • Real World Data: Customer medical records show improvement.

Functional Products

Image

Miracle Morning

2023 US Export

Image

Wonder Pterosin

Cognitive Support

World-Class Leadership

Gil Hong Park, MD, PhD

Founder & CEO

Professor Emeritus, Korea University. 40 years of dedication to R&D. Discovered Pterosin C & D as potent PKA activators.

Strategic Partners

Asan Medical Center Chungnam National Univ. K-MEDI Hub GBSA